Hu3F8 - Y-mAbs Therapeutics

Drug Profile

Hu3F8 - Y-mAbs Therapeutics

Alternative Names: Hu3F8 (GD2); Hu3F8-Fce; Humanised 3F8 - Y-mAbs Therapeutics; Humanised anti-GD2 3F8 monoclonal antibody - Y-mAbs Therapeutics

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Y-mAbs Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action GD2 ganglioside inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma; Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroblastoma; Osteosarcoma
  • Discontinued Breast cancer; Sarcoma; Small cell lung cancer

Most Recent Events

  • 12 Jun 2017 Memorial Sloan Kettering Cancer Center and Y-Mabs initiates enrolment in a phase I/II trial for Neuroblastoma (Combination therapy) in USA (NCT03189706)
  • 09 Sep 2016 Discontinued - Preclinical for Breast cancer in USA (Parenteral)
  • 09 Sep 2016 Discontinued - Preclinical for Sarcoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top